Iroquois Capital
Iroquois Capital is a private equity firm based in the United States that focuses on a range of investment stages, including seed to late stage, turnaround, growth capital, and PIPE investments. Founded in 2006 by John F. Jacques, the firm provides capital solutions to middle market companies. Iroquois Capital operates through its broker dealers and has a diverse portfolio that includes investments in various sectors, such as real estate investment trusts, captive services, insurance, and healthcare. Additionally, Iroquois Capital Advisors, a subsidiary of Iroquois Capital Group, offers brokerage services, security trading, and financial consulting from its Nashville, Tennessee location. Iroquois Security Monitoring, another entity under the Iroquois umbrella, specializes in acquiring and managing residential security alarm contracts, providing services related to burglary protection, fire safety, and emergency response systems.
Covenant Surgical Partners is a privately-held owner and operator of ambulatory surgery centers. Its services include using minimally invasive and robotic technology to screen for colorectal cancers, polyp removal, and surgery of the digestive tract as well as various examinations and diagnoses of the rectum area that enable patients to get proper detection of their diseases.
TapImmune engages in the discovery and development of immunotherapeutics for the treatment of cancer, infectious diseases, autoimmune disorders, and transplant tissue rejection. The company focuses on conducting studies using its transporters of antigen processing (TAP) gene technology in combination with an adeno virus. Its products include TAP cancer vaccine used for the treatment of breast cancer, prostate cancer, lung cancer, liver cancer, melanoma, renal cancer, and colorectal cancer. The company also develops vaccines for infectious diseases using its TAP gene technology. TapImmune has strategic relationships with University of British Columbia, Crucell Holland B.V., SAFC Pharma, Inc., and National Institute of Allergy and Infectious Diseases. The company was founded in 1999 and is based in Vancouver, Canada.
VeriTeQ is a technology company focused on animal and emergency identification solutions. Its products are utilized around the world in such applications as pet identification using its patented, FDA-approved implantable microchip; livestock identification and tracking using visual and radio frequency identification (RFID) ear tags; and global positioning systems (GPS) search and rescue beacons for use on aircraft, ships and boats, and by adventure enthusiasts. The company was founded in 1993 and headquartered in Delray Beach, Florida.
CEL-SCI Corporation, founded in 1983 and headquartered in Vienna, Virginia, focuses on the research and development of immunotherapy products to treat cancer and infectious diseases. The company's leading investigational therapy, Multikine, is currently undergoing phase III clinical trials for head and neck cancer. Additionally, CEL-SCI has developed a patented T-cell modulation process known as the Ligand Epitope Antigen Presentation System (LEAPS), which aims to enhance the immune response against a range of health issues, including bacterial, viral, and parasitic infections, as well as autoimmune diseases and allergies. The company is also working on LEAPS-H1N1-DC, CEL-2000, and CEL-4000 for rheumatoid arthritis, alongside LEAPS COV-19 to address COVID-19. CEL-SCI has partnered with the University of Georgia’s Center for Vaccines and Immunology to advance its COVID-19 immunotherapy initiatives.